It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Snakebite envenomation is a neglected tropical disease of high mortality and morbidity largely due to insufficient supply of effective and affordable antivenoms. Snake antivenoms are mostly effective against the venoms used in their production. It is thus crucial that effective and affordable antivenom(s) with wide para-specificity, capable of neutralizing the venoms of a large number of snakes, be produced. Here we studied the pan-specific antiserum prepared previously by a novel immunization strategy involving the exposure of horses to a ‘diverse toxin repertoire’ consisting of 12 neurotoxic Asian snake toxin fractions/ venoms from six species. This antiserum was previously shown to exhibit wide para-specificity by neutralizing 11 homologous and 16 heterologous venoms from Asia and Africa. We now show that the antiserum can neutralize 9 out of 10 additional neurotoxic venoms. Altogether, 36 snake venoms belonging to 10 genera from 4 continents were neutralized by the antiserum. Toxin profiles previously generated using proteomic techniques of these 36 venoms identified α-neurotoxins, β-neurotoxins, and cytotoxins as predominant toxins presumably neutralized by the antiserum. The bases for the wide para-specificity of the antiserum are discussed. These findings indicate that it is feasible to generate antivenoms of wide para-specificity against elapid neurotoxic venoms from different regions in the world and raises the possibility of a universal neurotoxic antivenom. This should reduce the mortality resulting from neurotoxic snakebite envenomation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Faculty of Science, Mahidol University, Department of Microbiology, Bangkok, Thailand (GRID:grid.10223.32) (ISNI:0000 0004 1937 0490); Chulabhorn Research Institute, Laboratory of Immunology, Bangkok, Thailand (GRID:grid.418595.4) (ISNI:0000 0004 0617 2559)
2 Faculty of Medicine, University of Malaya, Department of Molecular Medicine, Kuala Lumpur, Malaysia (GRID:grid.413018.f) (ISNI:0000 0000 8963 3111)
3 Faculty of Medicine, Chiang Mai University, Department of Microbiology, Chiang Mai, Thailand (GRID:grid.7132.7) (ISNI:0000 0000 9039 7662)
4 The Royal Thai Army, Veterinary Hospital, The Veterinary and Remount Department, Nakorn Pathom, Thailand (GRID:grid.7132.7)
5 Facultad de Microbiología, Universidad de Costa Rica, Instituto Clodomiro Picado, San José, Costa Rica (GRID:grid.412889.e) (ISNI:0000 0004 1937 0706)
6 People’s University of Medical and Health Sciences for Women, Anti Snake Venom/Anti Rabies Serology Laboratory, Nawabshah, Pakistan (GRID:grid.412889.e)
7 Faculty of Medicine, University of Malaya, Department of Pharmacology, Kuala Lumpur, Malaysia (GRID:grid.413018.f) (ISNI:0000 0000 8963 3111)